Trial Profile
A safety and tolerability study of subcutaneous trastuzumab (Herceptin®) for the treatment of patients with HER2-positive early breast cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2017
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab
- Indications Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms BELIS
- 20 Feb 2017 New trial record